indazoles has been researched along with imatinib mesylate in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (11.11) | 29.6817 |
| 2010's | 20 (74.07) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Dai, Y; Davidsen, SK; Glaser, KB; Guo, J; Marcotte, PA; McCall, JO; Michaelides, MR; Pease, LJ | 1 |
| Sherman, SI | 1 |
| Hu-Lowe, DD; Kuhnert, F; Kuo, CJ; Mancuso, MR; McDonald, DM; Sennino, B; Tabruyn, SP | 1 |
| Attkisson, E; Dai, Y; Grant, S; Jordan, N; Kolluri, N; Kramer, L; Muschen, M; Nguyen, N; Nguyen, T | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K | 1 |
| Debiec-Rychter, M; Deroose, CM; Fletcher, JA; Floris, G; Friedman, L; Li, H; Schöffski, P; Sciot, R; Van Looy, T; Vermaelen, P; Wellens, J; Wozniak, A | 1 |
| Bowlin, SJ; Robinson, KD; Stanek, EJ; Wang, W; Xia, F | 1 |
| Robert, C; Sibaud, V | 1 |
| Butrynski, JE; D'Adamo, D; Demetri, GD; Fisher, GA; Ganjoo, KN; George, S; Kamaya, A; McMillan, A; Morgan, JA; Villalobos, VM; Wagner, AJ | 1 |
| Behera, R; Mensa-Wilmot, K; Thomas, SM | 1 |
| Liang, H | 1 |
| Aldabagh, B; Joo, J; Yu, SS | 1 |
| Fukumoto, Y; Kubota, S; Morii, M; Nakayama, Y; Yamaguchi, N | 1 |
| Kato, S | 1 |
| Ceelen, W; De Wever, O; Descamps, B; Gremonprez, F; Izmer, A; Vanhaecke, F; Vanhove, C | 1 |
| Amler, L; Deininger, MW; Eiring, AM; Guan, Y; Hampton, G; Lackner, M; Lu, S; O'Hare, T; Wagle, M; Wang, Y; Wongchenko, M; Yan, Y | 1 |
| Adenis, A; Bertucci, F; Blay, JY; Bompas, E; Bouché, O; Cassier, P; Cesne, AL; Chauzit, E; Cropet, C; Duffaud, F; Gautier, J; Isambert, N; Italiano, A; Mir, O; Molimard, M; Pérol, D; Ray-Coquard, I; Rios, M; Toulmonde, M | 1 |
| Li, J | 1 |
| Akula, S; Duyster, J; Kamasani, S; Kancha, RK; Manga, V; Sivan, SK; Vudem, DR | 1 |
| Burger, DM; Desar, IME; Kweekel, DM; Lankheet, NAG; Mulder, SF; van der Graaf, WTA; van Erp, NP; van Herpen, CML | 1 |
| Fu, J; Liang, L; Pan, X; Si, R; Sun, Y; Wang, J; Zhang, J; Zhang, Q | 1 |
| Davare, MA; Druker, BJ; Joshi, SK; Tognon, CE | 1 |
| Belgioia, L; Bertulli, R; Buscaglia, M; Catalano, F; Comandini, D; Grassi, M; Rebuzzi, SE; Satragno, C | 1 |
| Desar, IME; Steeghs, N; van der Graaf, WTA; van Erp, NP; Westerdijk, K | 1 |
| Gomes, A; Mankoski, R; Miller, A; Nellesen, D; Norregaard, C; Proudman, D; Sullivan, E | 1 |
| Bria, E; Cintoni, M; Gasbarrini, A; Mele, MC; Pompili, M; Ponziani, FR; Pozzo, C; Raoul, P; Rinninella, E; Strippoli, A; Tortora, G | 1 |
8 review(s) available for indazoles and imatinib mesylate
| Article | Year |
|---|---|
Early clinical studies of novel therapies for thyroid cancers.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2008 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
Merkel cell carcinoma: current status of targeted and future potential for immunotherapies.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Biomarkers; Carcinoma, Merkel Cell; CD56 Antigen; Electrochemotherapy; Hepatitis A Virus Cellular Receptor 2; Humans; Imatinib Mesylate; Immunotherapy; Immunotherapy, Adoptive; Indazoles; Inhibitor of Apoptosis Proteins; Interferons; Interleukin-12; Interleukin-2; Ipilimumab; Lymphatic Metastasis; Membrane Proteins; Merkel cell polyomavirus; Oligonucleotides, Antisense; Piperazines; Polyomavirus Infections; Prognosis; Programmed Cell Death 1 Receptor; Pyrimidines; Receptors, Somatomedin; Skin Neoplasms; Somatostatin; Sulfonamides; Survivin; Thionucleotides; TOR Serine-Threonine Kinases | 2014 |
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Revisiting NTRKs as an emerging oncogene in hematological malignancies.
Topics: Animals; Benzamides; Chromosome Aberrations; Enzyme Inhibitors; Hematologic Neoplasms; Humans; Imatinib Mesylate; Indazoles; Mice; Oncogenes; Point Mutation; Prognosis; Pyrazoles; Pyrimidines; Receptor, trkA; Zebrafish | 2019 |
Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
Topics: Antineoplastic Agents; Drug Monitoring; Humans; Imatinib Mesylate; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sunitinib | 2020 |
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.
Topics: Gefitinib; Humans; Imatinib Mesylate; Indazoles; Muscle, Skeletal; Neoplasms; Phenylurea Compounds; Prognosis; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2021 |
2 trial(s) available for indazoles and imatinib mesylate
| Article | Year |
|---|---|
A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Piperazines; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Failure; Tumor Burden; Young Adult | 2014 |
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; France; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2016 |
17 other study(ies) available for indazoles and imatinib mesylate
| Article | Year |
|---|---|
Inhibition of phosphorylation of the colony-stimulating factor-1 receptor (c-Fms) tyrosine kinase in transfected cells by ABT-869 and other tyrosine kinase inhibitors.
Topics: 3T3 Cells; Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Binding Sites; Enzyme Inhibitors; Humans; Imatinib Mesylate; Indazoles; Kinetics; Lead; Mice; Phenylurea Compounds; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Signal Transduction; Transfection | 2006 |
Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Axitinib; Benzamides; Humans; Imatinib Mesylate; Imidazoles; Immunoglobulin Fc Fragments; Indazoles; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; Piperazines; Platelet-Derived Growth Factor; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1 | 2009 |
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Mice, Inbred BALB C; Mice, SCID; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Xenograft Model Antitumor Assays | 2011 |
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection | 2012 |
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Imatinib Mesylate; Indazoles; Mice; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Signal Transduction; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Twelve-month frequency of drug-metabolizing enzyme and transporter-based drug-drug interaction potential in patients receiving oral enzyme-targeted kinase inhibitor antineoplastic agents.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child; Cohort Studies; Databases, Pharmaceutical; Drug Interactions; Female; Humans; Imatinib Mesylate; Indazoles; Male; Middle Aged; Piperazines; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sulfonamides; United States; Young Adult | 2013 |
New chemical scaffolds for human african trypanosomiasis lead discovery from a screen of tyrosine kinase inhibitor drugs.
Topics: Animals; Axitinib; Benzamides; Erlotinib Hydrochloride; Female; HeLa Cells; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lapatinib; Mice; Morpholines; Piperazines; Protein Kinase Inhibitors; Purines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Trypanosomiasis, African | 2014 |
[Treatment strategy for recurrent and metastatic gastrointestinal stromal tumors].
Topics: Benzamides; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Indazoles; Indoles; Liver Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Recurrence; Sulfonamides; Sunitinib | 2014 |
Imatinib inhibits inactivation of the ATM/ATR signaling pathway and recovery from adriamycin/doxorubicin-induced DNA damage checkpoint arrest.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Checkpoint Kinase 1; DNA Damage; DNA Repair; Doxorubicin; Enzyme Activation; HeLa Cells; Humans; Imatinib Mesylate; Indazoles; Protein Kinases; Pyrimidines; Repressor Proteins; Signal Transduction; Sulfonamides; Tripartite Motif-Containing Protein 28 | 2015 |
Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Extracellular Fluid; HT29 Cells; Humans; Imatinib Mesylate; Indazoles; Infusions, Parenteral; Mice; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Peritoneal Absorption; Peritoneum; Pressure; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tumor Burden; Weight Loss; Xenograft Model Antitumor Assays | 2015 |
A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Topics: Apoptosis; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Drug Tolerance; Forkhead Box Protein O1; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Sulfonamides; Tumor Cells, Cultured | 2016 |
[Molecular mechanism of gastrointestinal stromal tumors and progress in drug research].
Topics: Benzimidazoles; Exons; Gastrointestinal Stromal Tumors; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Indazoles; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinolones; Succinate Dehydrogenase; Sulfonamides | 2016 |
Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
Topics: Axitinib; Computational Biology; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl | 2017 |
Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chromatography, High Pressure Liquid; Drug Monitoring; Feasibility Studies; Female; Humans; Imatinib Mesylate; Indazoles; Indoles; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Sunitinib; Tandem Mass Spectrometry; Treatment Outcome; Young Adult | 2017 |
Discovery of novel Bcr-Abl
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Cell Proliferation; Drug Design; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indazoles; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Docking Simulation; Mutation; Piperazines; Pliability; Protein Binding; Protein Kinase Inhibitors | 2019 |
Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Giant Cell Tumor of Tendon Sheath; Humans; Imatinib Mesylate; Indazoles; Pyrimidines; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2020 |
Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
Topics: Antineoplastic Agents; Budgets; Cost-Benefit Analysis; Formularies as Topic; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indazoles; Managed Care Programs; Medicaid; Medicare; Molecular Diagnostic Techniques; Phenylurea Compounds; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sulfonamides; Sunitinib; Treatment Failure; Triazines; United States | 2020 |